Clinical Trials Browser

Phase 2 × Lymphoma, Extranodal NK-T-Cell × camrelizumab × Clear all

NCT03363555 2020-06-18

SHR-1210 in Patients With Relapsed or Refractory Extranodal NK/T Cell Lymphoma

Phase 2 Unknown

Lymphoma, Extranodal NK-T-Cell

NCT03701022 2018-10-09

PD1 Combined With Apatinib in Patients With Relapsed or Refractory NK/T Cell Lymphoma

Phase 2 Unknown

Lymphoma, Extranodal NK-T-Cell